<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial treatment of epilepsy in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial treatment of epilepsy in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Initial treatment of epilepsy in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven Karceski, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Garcia, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 26, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Epilepsy is the syndrome of two or more unprovoked seizures that occur more than 24 hours apart [<a href="#rid1">1</a>]. Seizures affect people in many different ways. Seizures are disruptive in the lives of patients and can cause injury. People with epilepsy have higher rates of psychiatric comorbidity and may experience adverse psychosocial outcomes. Most worrisome is that people with epilepsy have an approximately threefold increased mortality compared with people who do not have seizures [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/114559.html" rel="external">"Comorbidities and complications of epilepsy in adults"</a>.)</p><p>This topic will discuss the approach to the initial treatment of seizures and epilepsy. Other topics discuss the evaluation of patients with seizures and epilepsy, other aspects of epilepsy therapy, and features of specific antiseizure medications. (See  <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">"Evaluation and management of the first seizure in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2214.html" rel="external">"Evaluation and management of drug-resistant epilepsy"</a> and  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">WHEN TO START ANTISEIZURE MEDICATION THERAPY</span></p><p class="headingAnchor" id="H845121317"><span class="h2">First-time unprovoked seizure</span><span class="headingEndMark"> — </span>The term unprovoked seizure refers to a seizure of unknown etiology as well as one that occurs in relation to a preexisting brain lesion or progressive nervous system disorder (often referred to as a remote symptomatic seizure). <strong>Unprovoked</strong> seizures are distinct from <strong>provoked</strong> seizures: provoked seizures are due to an acute condition such as a toxic or metabolic disturbance, immediately antecedent head trauma, or very recent/acute stroke (ie, acute symptomatic seizures).</p><p>The decision of whether or not to start antiseizure medication therapy at the time of a first unprovoked seizure in an adult should be individualized. The main factors to consider in making the decision are:</p><p class="bulletIndent1"><span class="glyph">●</span>The risk for recurrent seizures, which varies based on clinical factors discussed below (see <a class="local">'Risk of seizure recurrence'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The approximate benefit that can be expected from immediate antiseizure medication therapy on the risk of recurrent seizure (see <a class="local">'Benefit of early versus deferred treatment'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The side effect profiles of various antiseizure medication options, which vary based on individual patient comorbidities and age (see <a class="local">'Side effect profiles'</a> below and <a class="local">'Comorbid medical conditions'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient values and preferences, particularly with regard to the social consequences of a recurrent seizure (eg, implications for driving or employment) (see <a class="local">'Benefit of early versus deferred treatment'</a> below)</p><p></p><p>An evidence-based guideline of the American Academy of Neurology and the American Epilepsy Society on the management of an unprovoked first seizure in adults also advocates for an individualized approach that weighs the risk of seizure recurrence against the potential adverse effects of antiseizure medications. At the same time, the physician must consider educated patient preferences [<a href="#rid3">3</a>]. The guideline offers the following specific recommendations:</p><p class="bulletIndent1"><span class="glyph">●</span>Adults with an unprovoked first seizure should be informed that their seizure recurrence risk is greatest early within the first two years (21 to 45 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical variables associated with an increased risk may include a prior brain insult, an electroencephalogram (EEG) with epileptiform abnormalities, a significant brain imaging abnormality, and a nocturnal seizure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immediate antiseizure medication therapy, as compared with delay of treatment pending a second seizure, is likely to reduce recurrence risk within the first two years but may not alter the later occurrence of epilepsy (which is recurrent unprovoked seizures) nor improve quality of life. Over a longer term (&gt;3 years), immediate antiseizure medication treatment is unlikely to improve prognosis as measured by sustained seizure remission.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should be advised that the risk of antiseizure medication adverse events may range from 7 to 31 percent and that these adverse events are mostly mild and reversible.</p><p></p><p>In patients with a first unprovoked seizure who are found to have a central nervous system (CNS) abnormality on neuroimaging (such as a brain tumor or scar tissue from an old head injury or CNS infection), the risk of seizure recurrence is high. In this instance, most clinicians would start treatment after the <strong>first</strong> unprovoked seizure. In fact, such patients likely have a sufficiently high risk of seizure recurrence to meet criteria for epilepsy according to International League Against Epilepsy (ILAE) guidelines [<a href="#rid1">1</a>]. These criteria now consider patients with a single unprovoked seizure and an estimated risk of recurrence ≥60 percent over ten years to have epilepsy, similar to those with two unprovoked seizures occurring &gt;24 hours apart. (See  <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">"Evaluation and management of the first seizure in adults"</a> and <a class="local">'Risk of seizure recurrence'</a> below.)</p><p>The treatment of seizures in this high-risk group is very different from the management of patients with a first unprovoked seizure who have a normal (or nonfocal) examination and normal (or nonspecific) neuroimaging. In these patients, the risk of seizure recurrence is lower, and antiseizure medication therapy may be reasonably deferred until after a <strong>second</strong> unprovoked seizure.</p><p>Patient concerns also weigh heavily in treatment decisions. If the risk of seizure recurrence is low, and the individual places a high value on avoidance of side effects, antiseizure medication therapy may be delayed. In contrast, there are some individuals who will be very concerned about seizure recurrence. In this instance, an antiseizure medication may be initiated to reduce seizure recurrence, despite what may be a low likelihood of additional seizures.</p><p class="headingAnchor" id="H845121616"><span class="h3">Risk of seizure recurrence</span><span class="headingEndMark"> — </span>In prospective, randomized trials of individuals with a first unprovoked seizure, the estimated two-year recurrence risk in untreated patients ranges from 40 to 50 percent [<a href="#rid4">4-6</a>]. The risk of recurrence is highest in the first year after the seizure and diminishes with time; 80 to 90 percent of patients who have recurrent seizures do so within two years [<a href="#rid7">7,8</a>].</p><p>The most replicated clinical factors associated with an increased risk for seizure recurrence after a first unprovoked seizure include [<a href="#rid4">4-7,9-12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Epileptiform abnormalities on EEG (see  <a class="medical medical_review" href="/z/d/html/2233.html" rel="external">"Electroencephalography (EEG) in the diagnosis of seizures and epilepsy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Remote symptomatic cause, as identified by clinical history or neuroimaging (eg, brain tumor, brain malformation, head injury with loss of consciousness, prior central nervous system infection, or scarring from a prior brain injury or brain surgery)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal neurologic examination, including focal findings and intellectual disability</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A first seizure that occurs during sleep (ie, a nocturnal seizure)</p><p></p><p>Each of these factors has been associated with an approximately 2- to 2.5-fold increased risk for seizure recurrence. The studies that identified these factors were imperfect. Several were done in mixed groups of patients; in some of these studies, patients were on antiseizure medication treatment; in others, the patients were untreated. Moreover, there is a lack of information to guide clinicians about how these risk factors interact [<a href="#rid3">3</a>]: if the person has two or three of these risk factors, is their risk even higher?</p><p>Other potential risk factors for seizure recurrence have been investigated and remain more uncertain. As an example, patients who have a first presentation with status epilepticus or with multiple seizures within a single day are more likely to be treated with antiseizure medications than are those with a single short-duration seizure. However, limited data suggest that presentation with status epilepticus, in the absence of other risk factors, does not increase the risk of seizure recurrence [<a href="#rid6">6,7,9,13</a>]. Similarly, whether a history of prior febrile seizures is associated with an increased risk of seizure recurrence after a first unprovoked afebrile seizure is uncertain [<a href="#rid6">6,7,9,11</a>].</p><p>Study results have conflicted as to whether a family history of epilepsy impacts recurrence risk [<a href="#rid5">5-7,9,11</a>]. This varies according to the epilepsy syndrome, since several epilepsy syndromes have been identified as monogenetic in origin.</p><p class="headingAnchor" id="H845122419"><span class="h3">Benefit of early versus deferred treatment</span><span class="headingEndMark"> — </span>For adults presenting with an unprovoked first seizure, immediate antiseizure medication treatment reduces the risk of seizure recurrence by about 35 percent over the next one to two years [<a href="#rid4">4,5,10,14-18</a>]. This estimate is derived from a meta-analysis of five randomized trials (n = 1600 patients) comparing immediate versus delayed antiseizure medication therapy in adults with an unprovoked first seizure [<a href="#rid3">3</a>].</p><p>Although these studies show that treatment reduces seizure recurrence, they also suggest that starting an antiseizure medication has little impact on long-term outcome. In other words, at four and five years after the first seizure, patients have similar rates of complete seizure remission whether antiseizure medication treatment was initiated immediately after the first seizure or deferred until a second seizure occurred [<a href="#rid4">4,5,10,14,18</a>]. At least one randomized trial found that 20-year mortality was not impacted by immediate versus deferred treatment [<a href="#rid19">19</a>].</p><p>In the aggregate, quality of life outcomes, as measured in one randomized study, were not different with early versus deferred treatment [<a href="#rid20">20</a>]. However, the questionnaires showed that there was a tradeoff between the adverse effects of seizures versus adverse effects of taking antiseizure medications. These findings suggest that individual patient preferences should be considered when deciding between early versus delayed treatment of a single unprovoked seizure. As an example, patients randomized to early antiseizure medication treatment were more likely to be able to drive than patients whose treatment was deferred. A need to drive or operate heavy machinery along with other occupational and psychological consequences of suffering a recurrent seizure are important considerations when deciding whether to start antiseizure medication therapy.</p><p class="headingAnchor" id="H845121374"><span class="h2">Second unprovoked seizure</span><span class="headingEndMark"> — </span>Patients presenting with a second unprovoked seizure should be started on antiseizure medication therapy  (<a class="graphic graphic_algorithm graphicRef134331" href="/z/d/graphic/134331.html" rel="external">algorithm 1</a>), since seizure recurrence indicates that the patient has a substantially increased risk for additional seizures (ie, after two unprovoked seizures, they now carry the diagnosis of epilepsy) [<a href="#rid6">6,8</a>].</p><p>In one prospective case series, the risk of another seizure after two unprovoked seizures was 73 percent at four years (most of these patients were treated with antiseizure medications) [<a href="#rid8">8</a>]. After a single unprovoked seizure, a careful history may reveal that certain seizure types have already been happening. These more subtle clinical seizures include typical absence, myoclonic, and simple or complex partial. It is only with careful questioning that a patient may reveal or even realize that some of the symptoms they were previously experiencing were in fact epileptic seizures [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H845121380"><span class="h2">Acute symptomatic seizure</span><span class="headingEndMark"> — </span>Acute symptomatic seizures have a lower risk for subsequent epilepsy compared with remote symptomatic seizures [<a href="#rid21">21</a>]. Early management decisions, including whether or not to start an antiseizure medication, depend upon multiple factors, including the severity of the underlying illness, the cause and duration of the seizure, the expected risk of early recurrence, and the risks associated with a recurrent seizure. (See  <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">"Evaluation and management of the first seizure in adults", section on 'Acute symptomatic seizures'</a>.)</p><p>Patients with seizures that occur in the setting of acute severe neurologic illness or injury (eg, stroke, traumatic brain injury, meningitis, anoxic encephalopathy) are often treated with antiseizure medications in the acute setting because of the risk of prolonged recurrent seizures or aggravation of a systemic injury. (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Poststroke seizures'</a> and  <a class="medical medical_review" href="/z/d/html/2213.html" rel="external">"Posttraumatic seizures and epilepsy", section on 'Early posttraumatic seizures'</a> and  <a class="medical medical_review" href="/z/d/html/1084.html" rel="external">"Spontaneous intracerebral hemorrhage: Acute treatment and prognosis", section on 'Seizure management'</a>.)</p><p>A subset of acute symptomatic seizures is those that occur in the setting of an acute medical illness or metabolic disturbance  (<a class="graphic graphic_table graphicRef61807" href="/z/d/graphic/61807.html" rel="external">table 1</a>). In contrast to the setting of an acute stroke or traumatic brain injury, patients with seizures provoked by metabolic derangements are generally not felt to be at risk for future epilepsy, but they are at risk for seizure recurrence in the acute setting [<a href="#rid22">22</a>]. Short-term antiseizure medication therapy may be indicated if the metabolic disturbance is expected to persist or if the initial seizure is prolonged (as in the instance of status epilepticus). Most agree that if treatment is started for acute symptomatic seizures, it should be continued until the underlying illness has completely resolved  (<a class="graphic graphic_algorithm graphicRef134332" href="/z/d/graphic/134332.html" rel="external">algorithm 2</a>). However, the end point of antiseizure medication treatment may not be entirely clear in some cases. (See  <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">"Evaluation and management of the first seizure in adults", section on 'Acute symptomatic seizures'</a> and  <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">"Evaluation and management of the first seizure in adults", section on 'When to start antiseizure medication therapy'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">SELECTION OF AN ANTISEIZURE MEDICATION</span><span class="headingEndMark"> — </span>Epilepsy is initially treated with antiseizure medication monotherapy. Almost half of patients will become seizure-free with their first antiseizure medication trial [<a href="#rid23">23,24</a>]. However, as discussed below, clinical trials do not answer the most important question facing clinicians and patients: which is the best<em> </em>(most effective and<em> </em>best tolerated) antiseizure medication for new-onset seizures? Because no clear answer is at hand, clinicians must individualize the choice of antiseizure medication for each patient.</p><p>In choosing an initial therapy, clinicians must weigh relative efficacy and potential for adverse effects of each drug. Comparative efficacy and tolerability data are limited. Comparison trials that have been performed have not shown significant differences among various drugs in terms of efficacy. Clinicians must therefore formulate treatment plans based upon a combination of drug, seizure, and patient-specific factors.</p><p class="headingAnchor" id="H1016714749"><span class="h2">Drug-related considerations</span><span class="headingEndMark"> — </span>Aspects of antiseizure medication therapy that are relevant to drug selection include efficacy, pharmacokinetics, adverse effects, and cost.</p><p class="headingAnchor" id="H6"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>No single antiseizure medication is clearly the most effective or best tolerated, and there are now over 25 antiseizure medications approved for treatment of seizures in adults and/or children  (<a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef78021" href="/z/d/graphic/78021.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"</a>.)</p><p>The evidence is summarized in the sections that follow.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Randomized controlled trials</strong> – Randomized controlled trials (RCTs) are the least biased in assessing the efficacy and tolerability of treatments. However, RCTs of antiseizure medications are not without their problems: RCTs typically compare active therapy to a subtherapeutic dose of the same agent and/or to placebo rather than to an effective dose of another antiseizure medication [<a href="#rid25">25</a>]. Another limitation of most randomized trials in epilepsy is that these are usually performed testing new antiseizure medications as add-on treatment in patients with treatment-resistant (refractory) illness (see <a class="local">'FDA indications'</a> below). Such patients may not be representative of the general clinical population and may not accurately represent people who have new onset seizures or epilepsy. With new onset seizures, there is a gap between what is known and what is needed<em>.</em> </p><p></p><p class="bulletIndent1">There have been a limited number of randomized trials comparing various antiseizure medications head-to-head as initial monotherapy in adults. These have shown a similar effectiveness between the different drugs [<a href="#rid26">26,27</a>]. The randomized comparison trials provide some information but include a small number of currently available treatments:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">Carbamazepine</a> versus <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> [<a href="#rid28">28</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">Phenytoin</a> versus <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> [<a href="#rid29">29</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> versus <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid30">30</a>] or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> [<a href="#rid31">31</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">Lamotrigine</a> versus <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid32">32,33</a>] or <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> [<a href="#rid34">34</a>] or <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> [<a href="#rid35">35</a>] or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> [<a href="#rid36">36</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">Topiramate</a> versus <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> and <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid37">37</a>] or <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> [<a href="#rid38">38</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">Oxcarbazepine</a> versus <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> [<a href="#rid39">39,40</a>] or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> [<a href="#rid41">41</a>] or <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid42">42</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">Zonisamide</a> versus <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid43">43,44</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">Levetiracetam</a> versus <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> [<a href="#rid45">45-47</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">Lacosamide</a> versus <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid48">48</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">Carbamazepine</a> extended-release versus <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a>, <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a>, <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">lacosamide</a>, or <a class="drug drug_general" data-topicid="91586" href="/z/d/drug information/91586.html" rel="external">eslicarbazepine</a> [<a href="#rid49">49</a>]</p><p></p><p class="bulletIndent1">Although these trials have not shown significant differences between antiseizure medications, the quality of the data remains limited by the fact that they were generally of short duration (24 or 48 weeks). Such studies can compare the incidence of short-term side effects between drugs, but they have limited power to assess relative long-term efficacy. In general, but with some exceptions, these trials suggest that the newer antiseizure medications are superior with respect to tolerability [<a href="#rid27">27,50</a>]. There has never been a randomized trial that includes all available treatments. Such a trial would be massive, likely impractical, and obsolete as soon as a new drug (or treatment) became available </p><p></p><p class="bulletIndent1">A meta-analysis of randomized trials can potentially overcome some of the limitations of individual trials, but even these studies can be problematic, since patient populations and drug doses often vary between trials; this substantively limits the ability to compare the studied treatments. In general, such studies have lacked power either to refute or substantively confirm results of individual trials [<a href="#rid51">51-55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SANAD trials</strong> – The largest individual randomized trials examining different antiseizure medications as monotherapy for the initial treatment of epilepsy were the Standard and New Antiepileptic Drugs (SANAD) trials [<a href="#rid56">56-58</a>]. The first SANAD trials included 1721 patients with focal epilepsy and 716 patients with generalized and unclassifiable epilepsy; the SANAD II trial included 990 patients with focal epilepsy and 520 patients with generalized or unclassifiable epilepsy [<a href="#rid59">59,60</a>]. In an effort to balance methodologic rigor and practicality, the trials were not blinded [<a href="#rid61">61</a>]. The treating physician determined how quickly to titrate the medication, instead of following a standardized blinded protocol. This approach may have better approximated the "real life" use of these drugs than would a blinded trial. Outcome measures were time to treatment failure (for either inadequate seizure control or intolerable side effects) and time to achievement of a 12-month seizure remission. The main findings were:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients treated for focal epilepsy, the first SANAD trial found that <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> and <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a> had the longest time to treatment failure compared with <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, and <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> [<a href="#rid57">57</a>]. Lamotrigine and carbamazepine were associated with the shortest times to 12-month seizure remission. In the SANAD II trial, by intention-to-treat analysis, <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a> did not meet noninferiority criteria compared with lamotrigine for time to 12-month seizure remission and was inferior for time to treatment failure for any reason; in contrast, <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a> did meet the criteria for noninferiority compared with lamotrigine for time to 12-month seizure remission, but was also inferior for time to treatment failure [<a href="#rid59">59</a>]. Both levetiracetam and zonisamide were more likely to fail than lamotrigine due to adverse reactions, but not because of inadequate control of seizures.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients treated for generalized and unclassifiable epilepsy, the first SANAD trial found that <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> and <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> were superior to <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> in regard to time to treatment failure [<a href="#rid58">58</a>]. For time to 12-month seizure remission, valproate and topiramate were more efficacious compared with lamotrigine. In the SANAD II trial, by intention-to-treat analysis, <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a> did not meet noninferiority criteria compared with valproate for time to 12-month seizure remission [<a href="#rid60">60</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the first SANAD trial, quality of life outcomes were largely similar across treatment groups over a two-year period and did not show a clear advantage for any specific drug [<a href="#rid62">62</a>]. The strongest predictor of improved quality of life outcomes was achievement of a 12-month seizure remission.</p><p></p><p class="bulletIndent1">The investigators concluded that <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> should be considered the drug of first choice for focal epilepsy and <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> for generalized epilepsy [<a href="#rid57">57-60</a>]. Because the SANAD trials were unblinded, however, there was potential for bias. Also, they provided only sparse data regarding the potential of rare, often idiosyncratic, serious adverse events (eg, potential for teratogenicity with valproate). These results also do not account for other patient-specific preferences regarding the likelihood of different side effects, need for drug monitoring, potential for drug interactions, and dosing frequency [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expert opinion</strong> – Several articles have reviewed expert opinion and performed statistical analysis to summarize the recommendations regarding the choice of antiseizure medication for the treatment of adults and children with epilepsy [<a href="#rid64">64-67</a>]. As an example, a 2017 report summarized expert opinion regarding all available antiseizure medications (as of 2016) for the initial treatment of focal and generalized epilepsies [<a href="#rid65">65</a>]. In addition, the experts provided recommendations on special patient populations such as females of childbearing age, older adults, and those with intellectual challenges. Based upon data from the major trials [<a href="#rid56">56-60</a>], comprehensive reviews [<a href="#rid65">65</a>], and clinical experience of the contributors to this topic, the following antiseizure medications are reasonable choices for different clinical situations, with the exception that <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> should be avoided for females of childbearing age:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Initial treatment of focal epilepsy: <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">Lamotrigine</a>, <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a>, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">lacosamide</a> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetically mediated generalized epilepsies syndrome with mainly generalized tonic-clonic seizures: <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">Lamotrigine</a>, <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>, <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Absence seizures: <a class="drug drug_general" data-topicid="9440" href="/z/d/drug information/9440.html" rel="external">Ethosuximide</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetically mediated generalized epilepsy syndrome with myoclonic seizures: <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">Levetiracetam</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Female of childbearing age with either genetic generalized epilepsy or focal epilepsy: <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">Lamotrigine</a>, <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Older adult with focal epilepsy: <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">Lamotrigine</a>, <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a>, <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">lacosamide</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Comorbid depression with focal epilepsy: <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">Lamotrigine</a>, <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">lacosamide</a>, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Comorbid depression with genetically mediated generalized epilepsy: <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">Lamotrigine</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatic failure or after organ transplantation: <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">Levetiracetam</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">lacosamide</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Renal failure on hemodialysis: <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">Lamotrigine</a>, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>, <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a> </p><p></p><p class="bulletIndent1">We can look to the experts for guidance in choosing initial antiseizure therapy. These expert opinion reports can be viewed as similar to a consultation, but one that distills the opinions of a large group of epilepsy experts.</p><p></p><p class="headingAnchor" id="H1016715034"><span class="h3">Pharmacokinetics</span><span class="headingEndMark"> — </span>Important pharmacologic features of individual antiseizure medications are summarized in the table and reviewed in more detail separately  (<a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"</a>.)</p><p>Some of the more important considerations when choosing a first-line antiseizure medication include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing frequency</strong> – The half-lives of antiseizure medications vary considerably  (<a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">table 2</a>). For many individuals, the frequency with which a drug must be taken is an important factor in compliance (ie, adherence) and/or seizure control [<a href="#rid68">68</a>]. Optimal dose frequency for individual drugs can vary between patients.</p><p></p><p class="bulletIndent1">Most antiseizure medications are prescribed in two daily doses. Antiseizure medications that often require more frequent dosing include immediate-release <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="10144" href="/z/d/drug information/10144.html" rel="external">tiagabine</a>, regular and delayed-release <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>. Once daily dosing may be possible with <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a>, <a class="drug drug_general" data-topicid="91586" href="/z/d/drug information/91586.html" rel="external">eslicarbazepine</a>, <a class="drug drug_general" data-topicid="87037" href="/z/d/drug information/87037.html" rel="external">perampanel</a>, and extended-release formulations of <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a>, valproate, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>, <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>, and <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong> – The selection of an antiseizure medication should consider other prescribed medications for potential drug interactions. Clinicians should review each item on a patient's medication list for potential drug interactions [<a href="#rid69">69,70</a>]. Specific interactions of antiseizure medications with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1">In general, antiseizure medications with hepatic enzyme induction or inhibitory properties have the greatest potential for interactions. Induction of cytochrome P450 (CYP) enzymes occurs with all older antiseizure medications (<a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, and <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>) except <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> and <a class="drug drug_general" data-topicid="9440" href="/z/d/drug information/9440.html" rel="external">ethosuximide</a>. Enzyme induction also occurs with a few of the newer approved antiseizure medications such as <a class="drug drug_general" data-topicid="91586" href="/z/d/drug information/91586.html" rel="external">eslicarbazepine</a>, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>, <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a>, <a class="drug drug_general" data-topicid="9518" href="/z/d/drug information/9518.html" rel="external">rufinamide</a>, and <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>  (<a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">table 2</a>) [<a href="#rid61">61,71</a>].</p><p></p><p class="bulletIndent1">Antiseizure medications that are hepatic-enzyme inducers increase the metabolism of other medications that are broken down by the same pathway. As an example, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> induces the metabolism of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, potentially leading to subtherapeutic international normalized ratio (INR) and/or an increased dose requirement of warfarin. Commonly prescribed drugs with the potential to interact with enzyme-inducing antiseizure medications include statins, calcium channel blockers, serotonin reuptake inhibitors, antipsychotics, tricyclic antidepressants, hormonal contraceptive therapy, warfarin, and many anticancer drugs [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1">In contrast, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> is a hepatic enzyme inhibitor and may cause significant increases in serum concentrations of medications that are metabolized in the liver. Similarly, <a class="drug drug_general" data-topicid="93717" href="/z/d/drug information/93717.html" rel="external">stiripentol</a>, which is approved for Dravet syndrome, is a potent hepatic enzyme inhibitor. It is known to increase levels of the main metabolite of <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> (the 10,11 epoxide) [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1">Other drug interactions relate to protein binding. Addition of a drug that is highly protein-bound will displace another protein-bound drug, increasing its free fraction. In the setting of reduced serum albumin, this effect is amplified. Hormones can also affect the levels of some antiseizure medications. For instance, <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> concentrations are reduced by estrogen-containing hormonal contraceptives. (See <a class="local">'Hormonal contraception'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aging</strong> – Antiseizure medication use in older adult patients is complicated by several factors, including age-related alterations in protein binding, reduced hepatic metabolism, and diminished renal clearance of medications. In addition, polypharmacy is more often a concern in older adults. These and other factors related to antiseizure medication selection in older adults are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2225.html" rel="external">"Seizures and epilepsy in older adults: Treatment and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H1016716326"><span class="h3">Side effect profiles</span><span class="headingEndMark"> — </span>The adverse effects of antiseizure medications make a significant contribution to reduced quality of life in individuals with epilepsy [<a href="#rid74">74</a>]. While many antiseizure medication side effects (eg, drowsiness, dizziness, diplopia, and imbalance) seem to be common to this entire class of medicines, others are more specific to an individual drug. These should be considered in selecting an antiseizure medication since certain side effects are either more likely or more problematic in certain patients.</p><p>Common neurotoxic and systemic side effects are summarized in the table  (<a class="graphic graphic_table graphicRef59755" href="/z/d/graphic/59755.html" rel="external">table 4</a>). Less common, often idiosyncratic, but potentially serious adverse events are summarized separately  (<a class="graphic graphic_table graphicRef78896" href="/z/d/graphic/78896.html" rel="external">table 5</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurocognitive side effects</strong> – Most antiseizure medications are associated with a negative impact on cognition, but some are more problematic than others [<a href="#rid75">75</a>]. Among the older antiseizure medications, studies suggest that <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> is associated with greater impairments compared with <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, and <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, which have similar, but more modest negative effects [<a href="#rid76">76,77</a>]. Among the newer antiseizure medications, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> have been found to be less problematic than carbamazepine in their effects on cognition. Negative cognitive effects are similar with <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a> and carbamazepine [<a href="#rid78">78</a>]. Finally, a significant minority of patients taking <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> discontinue the drug because of clinically apparent cognitive difficulties. In direct comparison studies, cognitive profiles in patients taking topiramate were worse than those taking valproate, lamotrigine, or gabapentin [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypersensitivity reactions</strong> – Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS) are rare but severe idiosyncratic reactions, characterized by fever and mucocutaneous lesions. SJS and TEN have been most often associated with the use of <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, and <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>  (<a class="graphic graphic_table graphicRef78896" href="/z/d/graphic/78896.html" rel="external">table 5</a>), and less commonly with <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> and <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>; however, they have been described with almost all antiseizure medications [<a href="#rid79">79,80</a>].</p><p></p><p class="bulletIndent1">The period of highest risk is within the first two months of use. For <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>, and possibly <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, the risk is higher in patients with the HLA-B*1502 allele, which occurs almost exclusively in patients of Asian ancestry, including Indian. The US Food and Drug Administration (FDA) recommends screening such patients for the HLA-B*1502 allele prior to starting carbamazepine and oxcarbazepine. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Carbamazepine'</a> and  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Oxcarbazepine'</a> and  <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis", section on 'HLA polymorphism and pharmacogenetics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suicidality</strong> – Antiseizure medications as a class have been associated with an approximately twofold increased relative risk of suicidal behavior or ideation based on pooled analyses of placebo-controlled trials (0.43 versus 0.22 percent) [<a href="#rid81">81</a>]. Some experts advise screening for depression at diagnosis of epilepsy and at each follow-up visit [<a href="#rid82">82</a>]. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Specific adverse reactions'</a> and  <a class="medical medical_review" href="/z/d/html/114559.html" rel="external">"Comorbidities and complications of epilepsy in adults", section on 'Psychiatric disorders'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Weight gain or loss</strong> – Weight gain is associated with <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="10115" href="/z/d/drug information/10115.html" rel="external">vigabatrin</a>, <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, and <a class="drug drug_general" data-topicid="87037" href="/z/d/drug information/87037.html" rel="external">perampanel</a>. Weight loss has been reported with <a class="drug drug_general" data-topicid="8934" href="/z/d/drug information/8934.html" rel="external">felbamate</a>, <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>, and <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a>.</p><p></p><p class="headingAnchor" id="H1016715949"><span class="h3">FDA indications</span><span class="headingEndMark"> — </span>The FDA indication for use of antiseizure medications may influence physician prescribing habits. For many newer antiseizure medications, the FDA indications are based on studies that showed effectiveness as add-on treatment in persons with refractory epilepsy. Monotherapy trials are performed infrequently because most physicians and patients are reluctant to be treated with placebo when effective treatments exist [<a href="#rid25">25</a>]. As a result, many antiseizure medications are not FDA-approved as initial monotherapy. Some physicians may be initially reluctant to use newer antiseizure medications as monotherapy in the initial treatment of epilepsy pending advice from colleagues and/or published expert opinion.</p><p>A historical-controlled treatment discontinuation trial design is being increasingly used in an attempt to evaluate the effectiveness of various antiseizure medications as conversion to monotherapy in patients with drug-resistant epilepsy, since randomizing patients with active seizures to a placebo conversion presents ethical concerns. The primary outcome measure is the predicted exit percentage, defined as the proportion of patients meeting a seizure-related exit criterion (eg, withdrawal due to inadequate seizure control or adverse effects) at four months, compared with a pooled historical benchmark of 65 percent (compiled from older trials that did use a placebo or subtherapeutic antiseizure medication dose) [<a href="#rid83">83</a>]. Drugs shown to be more effective than this historical benchmark in prospective trials include <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> extended-release [<a href="#rid84">84</a>], <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a> extended-release [<a href="#rid85">85</a>], <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> [<a href="#rid86">86</a>], <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">lacosamide</a> [<a href="#rid87">87</a>], and <a class="drug drug_general" data-topicid="91586" href="/z/d/drug information/91586.html" rel="external">eslicarbazepine</a> [<a href="#rid88">88</a>]. The exit rate in these trials has ranged from 20 to 40 percent at four months.</p><p class="headingAnchor" id="H1016716039"><span class="h3">Cost of medications</span><span class="headingEndMark"> — </span>For many patients, the cost of their medication is also an issue and whether a specific antiseizure medication is on a list of preferred medications approved by a third-party payer may also be influential in the choice of antiseizure medication. When cost is taken into account, for areas of the world and for individual patients with restricted resources, older, less expensive medications such as <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> or <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> may be the treatment of choice for partial epilepsy [<a href="#rid89">89</a>]. Generic substitution can lower cost of many antiseizure medications. In rare instances, use of a generic may be associated with a change in seizure control or tolerability, although the magnitude of this risk has been debated. (See <a class="local">'Generic substitutions'</a> below.)</p><p class="headingAnchor" id="H1016714722"><span class="h2">Seizure and epilepsy syndrome-related considerations</span></p><p class="headingAnchor" id="H7"><span class="h3">Focal versus generalized seizures/epilepsy</span><span class="headingEndMark"> — </span>In selecting an antiseizure medication for a patient with new onset epilepsy, it is important to differentiate between a focal versus generalized epilepsy syndrome [<a href="#rid90">90</a>]. Antiseizure medications are classified as either broad or narrow spectrum agents  (<a class="graphic graphic_table graphicRef78021" href="/z/d/graphic/78021.html" rel="external">table 3</a>). While broad spectrum agents treat both focal and generalized epilepsy syndromes, narrow spectrum agents treat one or the other [<a href="#rid91">91</a>].</p><p>Most of the narrow spectrum agents are effective for localization-related or focal epilepsies. As an example, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> (a narrow spectrum agent) may work well for a patient with temporal lobe epilepsy (a focal epilepsy) but is unlikely to be effective in juvenile myoclonic epilepsy (a generalized epilepsy). <a class="drug drug_general" data-topicid="9440" href="/z/d/drug information/9440.html" rel="external">Ethosuximide</a> is another narrow spectrum agent used for absence seizures (a generalized epilepsy), which is generally ineffective for focal seizures. Broad spectrum agents are effective for both types of epilepsies [<a href="#rid92">92</a>]. If the clinician is unsure whether the epilepsy syndrome is focal or generalized, a broad spectrum agent is usually chosen  (<a class="graphic graphic_table graphicRef78021" href="/z/d/graphic/78021.html" rel="external">table 3</a>).</p><p>Identifying the correct epilepsy syndrome is critical to selecting an optimal treatment. For instance, a few of the narrow spectrum agents have been reported to worsen certain seizures that occur in the primary generalized epilepsy syndromes. <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">Oxcarbazepine</a> [<a href="#rid93">93</a>], <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="10115" href="/z/d/drug information/10115.html" rel="external">vigabatrin</a>, and <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> [<a href="#rid92">92</a>] have all been reported to worsen certain seizures types in generalized epilepsy syndromes.</p><p class="headingAnchor" id="H8"><span class="h3">Specific etiologies</span><span class="headingEndMark"> — </span>In addition to the distinction between generalized and focal epilepsy discussed above, specific etiologies of epilepsy may impact the treatment choice.</p><p class="bulletIndent1"><span class="glyph">●</span>Post-stroke epilepsy is generally easily controlled with antiseizure medication monotherapy [<a href="#rid94">94</a>]. The choice of antiseizure medication may be influenced by specific concerns, such as potential impact of the antiseizure medication on post-stroke functional recovery and the potential for drug interactions with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> and salicylates (see <a class="local">'Pharmacokinetics'</a> above) [<a href="#rid95">95</a>]. The treatment of post-stroke epilepsy is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Poststroke seizures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Brain tumors are associated with epilepsy in 30 to 70 percent of patients, depending on the tumor type. The choice of antiseizure medication in this setting is influenced by potential drug interactions with chemotherapeutic agents leading to decreased efficacy of both treatments, as well as the increased potential for allergic cutaneous reactions when antiseizure medications are used during radiotherapy [<a href="#rid96">96,97</a>]. Both of these factors contribute to a strong preference for non-enzyme inducing antiseizure medications in brain tumor patients when possible. (See  <a class="medical medical_review" href="/z/d/html/5181.html" rel="external">"Seizures in patients with primary and metastatic brain tumors"</a>.)</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Comorbid medical conditions</span><span class="headingEndMark"> — </span>Medical comorbidities are important to consider when selecting an antiseizure medication. Many antiseizure medications are either metabolized by the liver, excreted by the kidneys, or both  (<a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">table 2</a>). When a person has hepatic or renal disease, it may be necessary to avoid certain antiseizure medications or to adjust the dose. Other comorbidities can be problematic because of potential drug side effects or drug interactions, while others may represent an opportunity to choose an antiseizure medication that has efficacy in both conditions. Specific interactions of antiseizure medications with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p class="headingAnchor" id="H15"><span class="h3">Renal disease</span><span class="headingEndMark"> — </span>Renally excreted drugs include <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>, <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a>, <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">lacosamide</a>, <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a>, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>, and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>  (<a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">table 2</a>) [<a href="#rid91">91,98,99</a>]. The dose of these drugs should be adjusted based on the severity of renal impairment  (<a class="graphic graphic_table graphicRef109485" href="/z/d/graphic/109485.html" rel="external">table 6</a>).</p><p>In patients on hemodialysis, antiseizure medication regimens should be individualized based on drug levels and clinical response. The renally excreted drugs and some others (eg, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>) are removed by hemodialysis, and a low dose should be supplemented after dialysis to maintain therapeutic levels. The effects of peritoneal dialysis on antiseizure medication metabolism are not well studied, and antiseizure medication treatment in such patients may require additional monitoring. (See  <a class="medical medical_review" href="/z/d/html/1894.html" rel="external">"Seizures in patients undergoing hemodialysis", section on 'Dosing'</a>.)</p><p>Highly protein-bound antiseizure medications exhibit altered pharmacokinetics, including greater therapeutic and toxic effects and drug interactions, when given in usual doses to patients with low serum albumin or protein-binding affinity (eg, due to nephrotic syndrome or acidosis). Albuminuria (causing low serum albumin) and acidosis reduce protein binding fractions and binding affinity, leading to increased fractions of free drug [<a href="#rid98">98</a>]. For highly protein-bound antiseizure medications  (<a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">table 2</a>), subtherapeutic total drug levels may be both sufficient for efficacy and required to avoid toxicity in this setting. Free drug levels of <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> may be monitored, but such tests are less routinely available for other antiseizure medications.</p><p><a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">Topiramate</a> and <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a> are associated with nephrolithiasis and should probably be avoided in patients with a history of or who are prone to this condition (see  <a class="medical medical_review" href="/z/d/html/7375.html" rel="external">"Kidney stones in adults: Epidemiology and risk factors"</a>). Renal tubular acidosis can also occur with these antiseizure medications; patients with preexisting conditions that make them prone to metabolic acidosis (eg, severe respiratory disorders, diarrhea) should also consider avoiding these drugs or have more frequent monitoring of serum bicarbonate levels [<a href="#rid100">100</a>].</p><p>In the setting of renal transplantation, potential drug interactions between antiseizure medications and immunosuppressive therapy should be considered. Enzyme-inducing antiseizure medications may lower serum immunosuppressant levels, while enzyme-inhibitors may increase levels.</p><p class="headingAnchor" id="H16"><span class="h3">Hepatic disease</span><span class="headingEndMark"> — </span>Some antiseizure medications are associated with hepatic toxicity and should be avoided in patients with preexisting liver disease. These include <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> and <a class="drug drug_general" data-topicid="8934" href="/z/d/drug information/8934.html" rel="external">felbamate</a>, and to a lesser extent, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> and <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid98">98,101</a>]. Many other antiseizure medications are metabolized fully or partially in the liver  (<a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">table 2</a>), requiring caution and dose adjustment when used in patients with chronic liver disease. These include carbamazepine, <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, phenytoin, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="8719" href="/z/d/drug information/8719.html" rel="external">clobazam</a>, valproate, felbamate, <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a>, <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>, <a class="drug drug_general" data-topicid="91586" href="/z/d/drug information/91586.html" rel="external">eslicarbazepine</a>, and <a class="drug drug_general" data-topicid="106990" href="/z/d/drug information/106990.html" rel="external">brivaracetam</a>. <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">Levetiracetam</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, and <a class="drug drug_general" data-topicid="10115" href="/z/d/drug information/10115.html" rel="external">vigabatrin</a> do not undergo hepatic metabolism and are less problematic for use in patients with chronic liver disease.</p><p class="headingAnchor" id="H17"><span class="h3">Psychiatric disorders</span><span class="headingEndMark"> — </span>Persons with epilepsy have a higher than expected prevalence of comorbid psychiatric disorders [<a href="#rid64">64,102-105</a>]. The association may relate to shared perturbations in neurotransmitter action, alterations to neural networks or both [<a href="#rid102">102,104,106</a>]. In persons with epilepsy, the presence of depression correlates more strongly with a poor quality of life than the frequency of the seizures [<a href="#rid107">107</a>].</p><p>Some antiseizure medications (<a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>) appear to have mood-stabilizing properties [<a href="#rid108">108-110</a>]. Their efficacy in this regard is best established for bipolar disorder. However, many physicians view these medications as attractive in patients with comorbid anxiety and depression.</p><p>In contrast, some antiseizure medications, in particular those that potentiate gamma-aminobutyric acid (GABA) neurotransmission (<a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="10144" href="/z/d/drug information/10144.html" rel="external">tiagabine</a>, <a class="drug drug_general" data-topicid="10115" href="/z/d/drug information/10115.html" rel="external">vigabatrin</a>, <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>), have been reported to cause or exacerbate a depressed mood and perhaps should be avoided in patients with comorbid depression [<a href="#rid111">111</a>]. Similarly, drugs that have been reported to provoke psychosis (<a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a>, topiramate, vigabatrin, <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">zonisamide</a>, <a class="drug drug_general" data-topicid="9440" href="/z/d/drug information/9440.html" rel="external">ethosuximide</a>, and <a class="drug drug_general" data-topicid="87037" href="/z/d/drug information/87037.html" rel="external">perampanel</a>) may be less desirable in patients with that history. In the Columbia-Yale study, neuropsychiatric side effects were reported in 17 percent of patients taking antiseizure medications. Levetiracetam was associated with the highest rate (22 percent) while zonisamide had the second highest rate (9.7 percent) of neuropsychiatric side effects. In comparison, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="8719" href="/z/d/drug information/8719.html" rel="external">clobazam</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, and <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> were significantly associated with a decreased rate of psychiatric or behavioral side effects [<a href="#rid112">112</a>]. </p><p>Use of one of the antiseizure medications thought to be effective in mood stabilization does not substitute for a full psychiatric evaluation and independent treatment of a coexisting psychiatric disorder. Further impetus for this comes from the fact that as a class, antiseizure medications are associated with an increased risk of suicide. All patients with epilepsy treated with antiseizure medications should be monitored for changes in mood and suicidality. (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Specific adverse reactions'</a>.)</p><p>Drug interactions are also a potential concern in patients with psychiatric disorders. Enzyme-inducing antiseizure medications  (<a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">table 2</a>) can decrease the plasma concentration of many antidepressants including tricyclic agents and selective serotonin reuptake inhibitors, as well as antipsychotic drugs and benzodiazepines [<a href="#rid69">69,70</a>].</p><p class="headingAnchor" id="H18"><span class="h3">Migraine</span><span class="headingEndMark"> — </span>Some studies suggest that migraine may be more prevalent in patients with epilepsy and vice versa [<a href="#rid113">113,114</a>]. <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">Valproate</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, and <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> are antiseizure medications that have demonstrated efficacy for migraine prevention in placebo-controlled trials (see  <a class="medical medical_review" href="/z/d/html/3345.html" rel="external">"Preventive treatment of episodic migraine in adults", section on 'Anticonvulsants'</a>). This may provide an opportunity to limit polypharmacy in individuals with both migraine and epilepsy.</p><p class="headingAnchor" id="H19"><span class="h3">Osteoporosis risk</span><span class="headingEndMark"> — </span>Antiseizure medications in chronic use have been associated with bone loss. Initially this association was observed for enzyme-inducing antiseizure medications  (<a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">table 2</a>), but later was found to extend to <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> as well as to some of the newer nonenzyme-inducing antiseizure medications [<a href="#rid115">115-117</a>]. The evidence associating osteoporosis and antiseizure medication therapy may be strongest for <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>. Osteoporosis is particularly problematic for patients with epilepsy, as seizures are associated with falls and bone fractures [<a href="#rid100">100,118,119</a>].</p><p>While <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> should perhaps be avoided in patients in whom there is concern for bone loss, there are insufficient data to recommend avoiding or choosing any other specific antiseizure medication in order to limit the risk of osteoporosis [<a href="#rid100">100</a>]. Rather, monitoring of bone density, routine supplementation of calcium and vitamin D, and a consistent exercise regimen are suggested for all patients on chronic antiseizure medication therapy. (See  <a class="medical medical_review" href="/z/d/html/2063.html" rel="external">"Antiseizure medications and bone disease"</a>.)</p><p class="headingAnchor" id="H20"><span class="h3">Others</span></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes – Because of its association with weight gain, insulin resistance, and polycystic ovarian syndrome, use of <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> in individuals with diabetes or obesity should be carefully considered [<a href="#rid120">120</a>]. <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">Carbamazepine</a>, <a class="drug drug_general" data-topicid="10115" href="/z/d/drug information/10115.html" rel="external">vigabatrin</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> are also, but much less frequently, associated with weight gain. (See <a class="local">'Side effect profiles'</a> above.)</p><p></p><p class="bulletIndent1">Some antiseizure medications (<a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, and possibly <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>) have efficacy in treating pain associated with diabetic neuropathy. (See  <a class="medical medical_review" href="/z/d/html/5280.html" rel="external">"Management of diabetic neuropathy", section on 'Pain management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid disease – While many antiseizure medications, in particular the enzyme-inducing agents, can alter thyroid hormone levels, this is generally subclinical and should not impact drug choice [<a href="#rid120">120,121</a>]. Enzyme-inducing agents should probably be avoided in patients with severe thyroid dysfunction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cancer – The choice of antiseizure medication in patients being treated for systemic cancer is influenced by potential drug interactions between enzyme-inducing antiseizure medications  (<a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">table 2</a>) and chemotherapeutic agents that can lead to decreased efficacy of both treatments [<a href="#rid96">96,97</a>]. By inhibiting their metabolism, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> may increase the toxicity of certain cancer chemotherapy agents. There also may be an increased potential for allergic cutaneous reactions when antiseizure medications are used during radiotherapy; however, there is no way to predict which patients are more at risk for this particular side effect.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV – Enzyme-inducing antiseizure medications and those that are highly protein-bound  (<a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">table 2</a>) may interact with antiretroviral therapy (ART) [<a href="#rid122">122-124</a>]. Of particular concern is that these drug interactions may cause minor reductions in the levels of protease inhibitors that could lead to loss of viral suppression and the emergence of drug resistance. There are also concerns that phenytoin-associated skin rash may be more common in HIV-positive patients. <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">Lamotrigine</a> doses may need to be increased with certain medications including <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a> and <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">atazanavir</a>. While early in vitro studies suggested that <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> might increase viral replication, a series of patients treated with valproate maintained excellent control of both seizures and HIV [<a href="#rid125">125</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular disease – Clinicians should consider potential drug interactions between cytochrome P450 (CYP) enzyme-inducing antiseizure medications (ie, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="91586" href="/z/d/drug information/91586.html" rel="external">eslicarbazepine</a>, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a>, <a class="drug drug_general" data-topicid="9518" href="/z/d/drug information/9518.html" rel="external">rufinamide</a>, and <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>) and statins, calcium channel blockers, and <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid69">69,70,126</a>]. While carbamazepine has been associated with heart block and other bradyarrhythmias in susceptible individuals [<a href="#rid127">127</a>], clinically significant electrocardiography (ECG) changes are uncommon with carbamazepine in older adult patients who do not have a preexisting conduction defect [<a href="#rid128">128</a>].</p><p></p><p class="bulletIndent1">Because the CYP enzymes are involved in cholesterol synthesis, it is possible that enzyme-inducing antiseizure medications may thereby affect vascular risk. In one small series, switching patients from <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> or <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> to noninducing antiseizure medications <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">levetiracetam</a> or <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> was associated with improvements in serologic markers of vascular risk (eg, total cholesterol, triglycerides, C-reactive protein) [<a href="#rid129">129</a>]. Some studies have found that long-term monotherapy with carbamazepine, phenytoin, or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, is associated with markers of increased cardiovascular risk, such as carotid intimal thickening, abnormal cholesterol, homocysteine, and folate metabolism, and elevated levels of C-reactive protein [<a href="#rid130">130,131</a>]. However, it is unclear whether enzyme-inducing antiseizure medications are associated with a greater risk of cardiovascular disease than nonenzyme-inducing antiseizure medications, as the evidence is inconsistent [<a href="#rid132">132,133</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood disorders – Certain antiseizure medications (<a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9440" href="/z/d/drug information/9440.html" rel="external">ethosuximide</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>) are associated with neutropenia and agranulocytosis, and should be avoided in patients with blood disorders [<a href="#rid134">134,135</a>]. (See  <a class="medical medical_review" href="/z/d/html/8374.html" rel="external">"Drug-induced neutropenia and agranulocytosis"</a>.)</p><p></p><p class="bulletIndent1">Similarly, drugs associated with thrombocytopenia (eg, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>) should be avoided in patients with a low platelet count or a history of other bleeding diatheses. (See  <a class="medical medical_review" href="/z/d/html/6674.html" rel="external">"Drug-induced immune thrombocytopenia"</a>.)</p><p></p><p class="headingAnchor" id="H21"><span class="h2">Women of childbearing age</span><span class="headingEndMark"> — </span>A number of issues are important in women of childbearing age, especially if they are considering becoming or are already pregnant.</p><p>Folate should be prescribed to all women of childbearing age who are taking antiseizure medications. (See  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Folic acid supplementation'</a>.)</p><p class="headingAnchor" id="H22"><span class="h3">Hormonal contraception</span><span class="headingEndMark"> — </span>Women should be informed about the interactions between antiseizure medication therapies and hormonal pill, patch, or ring contraception and the availability of long-acting reversible contraception (LARC), which is highly effective and avoids most if not all drug-drug interactions, depending on the specific method. (See  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Preconception management'</a> and  <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>.)</p><p>The expected contraceptive failure rate of 0.7 per 100 woman-years using oral contraceptives is increased to 3.1 per 100 woman-years in patients who concomitantly take enzyme-inducing antiseizure medications  (<a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">table 2</a>) [<a href="#rid136">136-139</a>]. While <a class="drug drug_general" data-topicid="10115" href="/z/d/drug information/10115.html" rel="external">vigabatrin</a> is not an enzyme inducer, lower levels of ethinyl estradiol have been reported in volunteers taking this antiseizure medication [<a href="#rid140">140</a>] (see  <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Drug interactions'</a>). If an enzyme-inducing antiseizure medication is nonetheless deemed to be the drug of choice in a woman taking combined hormonal pill, patch, or ring contraception, alternative regimens or forms of contraception should be considered. (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Contraception'</a>.)</p><p>In addition to the effect of antiseizure medications on hormonal contraceptive metabolism, combined hormonal contraceptives can increase the metabolism of <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, thereby reducing the plasma drug concentration. In other words, higher doses of lamotrigine may be needed in women taking combined estrogen-progesterone contraception, and continuous dosing may be preferable to avoid increased lamotrigine levels during pill-free intervals. (See  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Lamotrigine'</a>.)</p><p class="headingAnchor" id="H23"><span class="h3">Catamenial epilepsy</span><span class="headingEndMark"> — </span>Many women with epilepsy report an association between the occurrence of their seizures and certain phases of their menstrual cycle [<a href="#rid141">141,142</a>]. Catamenial seizure clustering can occur in women with any seizure type and epilepsy syndrome but may be more common among women with focal compared with generalized epilepsy [<a href="#rid143">143-148</a>] and among those with left-sided temporal epilepsy compared with right-sided, multifocal, or extratemporal epilepsy [<a href="#rid149">149,150</a>].</p><p>In general, research suggests that catamenial seizure patterns result from cyclic changes in hormone levels during the menstrual cycle; changes in antiseizure medication levels due to endogenous metabolic effects may also contribute. Estrogen levels peak mid-cycle and then, in women who do not conceive, fall through the onset of menses. It is during the late part of the menstrual cycle (just before the onset of menses), during a relative drop in estrogen levels, that seizures most often cluster [<a href="#rid143">143,151</a>]. Periovulatory (mid-cycle) seizure clustering can also occur.</p><p>The mainstay of treatment of catamenial seizures is an antiseizure medication that is most effective for the woman's epilepsy syndrome. However, when catamenial seizures are not controlled with antiseizure medications, clinicians may consider use of a continuous estrogen-progestin contraceptive on the theoretical basis that suppressing estrogen fluctuations will lead to better seizure control. The rationale and use of hormonal prophylaxis for catamenial epilepsy is similar to that in estrogen-associated migraine, which is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5441.html" rel="external">"Estrogen-associated migraine headache, including menstrual migraine"</a>.)</p><p>Intermittent benzodiazepine treatment timed according to the vulnerable phase of the menstrual cycle is also a common strategy. <a class="drug drug_general" data-topicid="8719" href="/z/d/drug information/8719.html" rel="external">Clobazam</a> is the only benzodiazepine studied systematically for this purpose. In a double-blind cross-over study, clobazam (20 to 30 mg/day) was administered for 10 days in the high-risk phase of the menstrual cycle in 18 women with catamenial epilepsy [<a href="#rid152">152</a>]. Fourteen patients reported better seizure control with clobazam than placebo. Long-term follow-up of patients who continued to use this treatment strategy revealed seizure remission and/or significant reduction of seizures in five of nine patients [<a href="#rid153">153</a>]. These limited data support a fairly common practice of treating catamenial seizure exacerbations with intermittent benzodiazepines with a long-acting agent such as <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>. A reasonable dose of lorazepam in this setting is 0.5 to 1 mg two to three times daily.</p><p>Very limited data suggest that appropriately timed <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">acetazolamide</a> may have some benefit in catamenial epilepsy [<a href="#rid154">154-156</a>]. Although cyclic natural progesterone has been reported to reduce seizure frequency in observational studies, a randomized trial failed to confirm a benefit in 294 women with poorly controlled seizures [<a href="#rid157">157</a>]. Other investigational strategies include gonadotropin analogs and neurosteroids such as <a class="drug drug_general" data-topicid="135301" href="/z/d/drug information/135301.html" rel="external">ganaxolone</a> [<a href="#rid144">144,158-160</a>].</p><p class="headingAnchor" id="H24"><span class="h3">Pregnancy and postpartum</span><span class="headingEndMark"> — </span>Treatment of epilepsy during pregnancy must balance competing risks. Seizures, particularly convulsive seizures, are believed to be harmful to the fetus. At the same time, both major and minor malformations are more common in fetuses exposed to antiseizure medications in utero compared with offspring of untreated women with epilepsy and women without epilepsy. The overall risk of major malformations is 4 to 6 percent in exposed infants; <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> is a major contributor to this risk. Polypharmacy increases the risk. The timing (early versus late in gestation) and dose of exposure are also likely to be important. While no antiseizure medication has been definitively shown to be safe in pregnancy, the evidence linking valproate to fetal malformations is sufficiently convincing to recommend avoiding its initiation and use in most women of childbearing potential [<a href="#rid161">161</a>]. (See  <a class="medical medical_review" href="/z/d/html/2218.html" rel="external">"Risks associated with epilepsy during pregnancy and the postpartum period"</a>.)</p><p>The management of epilepsy in pregnancy and during breastfeeding is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period"</a>.)</p><p class="headingAnchor" id="H1016717634"><span class="h1">INITIATION OF ANTISEIZURE MEDICATION THERAPY</span></p><p class="headingAnchor" id="H1016717770"><span class="h2">Patient education</span><span class="headingEndMark"> — </span>The management of patients with epilepsy is focused on three main goals: controlling seizures, avoiding, or minimizing treatment side effects, and maintaining or restoring quality of life. Successful treatment can be optimized by a systematic approach that includes patient education [<a href="#rid162">162,163</a>]. Before treatment is initiated, the physician needs to counsel the patient and family to increase their understanding of epilepsy and their ability to report necessary and relevant information. These discussions will improve the likelihood that the patient will comply with the plan of treatment.</p><p>The physician should impress upon the patient, family, and patient's friends the critical need to follow the prescribed drug regimen. Nonadherence to antiseizure medication treatment regimen is associated with increased risk of mortality, as well as hospitalization and injury [<a href="#rid164">164</a>]. (See  <a class="medical medical_review" href="/z/d/html/114559.html" rel="external">"Comorbidities and complications of epilepsy in adults"</a>.)</p><p>Written instructions on how and when to take the drugs should be provided and should explain the dosing regimen and any potential adverse effects or drug-drug interactions. The patient must also be warned not to stop taking an antiseizure medication on their own initiative, and not to allow a prescription to run out or expire.</p><p>Patients should be urged not to start any other prescription, over-the-counter medications, dietary supplements, or herbal remedies without first contacting their physician because these might affect serum concentrations of their antiseizure medications [<a href="#rid72">72,165</a>]. (See <a class="local">'Pharmacokinetics'</a> above.)</p><p class="headingAnchor" id="H1016717833"><span class="h2">Drug administration and dosing</span><span class="headingEndMark"> — </span>Treatment should be started with a single drug (monotherapy). In general, the strategy is to gradually titrate the dosage to that which is maximally tolerated and/or produces optimal seizure control (start low and go slow). Pooled analysis from two large prospective studies found that with this approach, adverse event reporting was no higher in treated versus untreated patients [<a href="#rid166">166</a>]. Variables other than antiseizure medication treatment were found to be associated with adverse event reporting, most notably comorbid depression. The recommended initial dose and suggested titration schedule is presented separately. (See  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"</a>.)</p><p class="headingAnchor" id="H29"><span class="h2">Seizure calendar</span><span class="headingEndMark"> — </span>Patients and family members should be asked to record seizures and antiseizure medication doses on a calendar, which can then be brought or sent to the physician for review. Seizure triggers (eg, stress, sleep deprivation, alcohol, menses) should be indicated. The patient and family should note on the calendar the hour at which any symptoms occur.</p><p>The seizure calendar helps to monitor and encourage compliance, as well as identify triggers. The seizure calendar also may be used to track the patient's response to drug therapy, including possible side effects. In one study of 71 patients completing daily seizure diaries, both lack of sleep and higher self-reported stress and anxiety were associated with seizure occurrence [<a href="#rid167">167</a>]. Seizures were also associated with the patients' own prediction of the likelihood of seizure occurrence. Physicians should be aware that patients are often unaware of their seizures and may significantly underestimate the number of seizures that occur, especially those that occur during sleep or that disrupt consciousness [<a href="#rid168">168</a>].</p><p class="headingAnchor" id="H31"><span class="h2">Laboratory monitoring</span><span class="headingEndMark"> — </span>A complete blood count, liver function tests, blood urea nitrogen (BUN), and measurement of creatinine and electrolytes levels should be done prior to starting antiseizure medication therapy. Albumin levels should also be obtained prior to starting treatment with one of the highly protein-bound antiseizure medications.</p><p>Regular follow-up visits should be scheduled to check drug concentrations, blood counts, and hepatic and renal function. These visits are also used to address concerns the patient may have about taking the medication and possible side effects, or psychosocial aspects of their disorder. Drug levels should be checked at least yearly in patients who are not having seizures and not undergoing medication dose changes. Chemistry and hematology studies are usually checked in association with drug levels.</p><p>Drug levels can be helpful in the management of antiseizure medications [<a href="#rid169">169</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>To establish an individual therapeutic concentration when a patient is in remission</p><p class="bulletIndent1"><span class="glyph">●</span>To assist in the diagnosis of clinical antiseizure medication toxicity</p><p class="bulletIndent1"><span class="glyph">●</span>To assess compliance</p><p class="bulletIndent1"><span class="glyph">●</span>To guide dose adjustments, particularly in the setting of drug formulation changes, when an interacting medication is added to or removed from a patient's regimen, or during pregnancy</p><p></p><p class="headingAnchor" id="H1016718238"><span class="h2">Generic substitutions</span><span class="headingEndMark"> — </span>The use of generic medications as a treatment for people with epilepsy has attracted much attention and debate, and the evidence is mixed in terms of whether generic substitution of antiseizure medications has an adverse impact on seizure control and toxicity. Clinicians should consider the possibility of generic substitution as a cause of unexpected breakthrough seizures or toxicity, along with other possible explanations. In addition, clinicians may wish to obtain laboratory monitoring with plasma drug levels when a change is made in drug formulation. This topic is reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Generic substitution'</a>.)</p><p class="headingAnchor" id="H47269980"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113971.html" rel="external">"Society guideline links: Seizures and epilepsy in adults"</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15501.html" rel="external">"Patient education: Seizures (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16568.html" rel="external">"Patient education: Epilepsy in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/735.html" rel="external">"Patient education: Seizures in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H33"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p>When the diagnosis of epilepsy is made, the initial treatment is a single antiseizure medication. When to start treatment, and with what agent, is a complex decision that is individualized in order to optimize both efficacy and tolerability.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to start antiseizure medication</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>First unprovoked seizure</strong> – The decision of whether to start antiseizure medication therapy at the time of a first unprovoked seizure in an adult should be individualized. The decision is based on several factors: an assessment of the risk for recurrent seizure, the potential benefits of immediate antiseizure medication therapy in reducing the risk of recurrent seizure, the side effects of antiseizure medications, and patient preferences. (See <a class="local">'First-time unprovoked seizure'</a> above.)</p><p></p><p class="bulletIndent2">Antiseizure medication treatment is reasonable in patients after a single unprovoked seizure if they also have a potential symptomatic cause of epilepsy (eg, stroke or trauma history, brain tumor), epileptiform features on electroencephalogram, a relevant abnormality on neuroimaging study (computed tomography [CT] or magnetic resonance imaging [MRI]), or an abnormal neurologic examination. Many of these patients likely meet criteria for epilepsy according to the International League Against Epilepsy (ILAE) definition, which considers patients with a single unprovoked seizure and an estimated risk of recurrence ≥60 percent over ten years to have epilepsy, similar to those with two unprovoked seizures occurring &gt;24 hours apart. (See <a class="local">'Risk of seizure recurrence'</a> above.)</p><p></p><p class="bulletIndent2">Antiseizure medication treatment after a single unprovoked seizure in patients may be deferred depending on the presence or absence of other risk factors and on individual patient preferences. (See <a class="local">'Benefit of early versus deferred treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Second unprovoked seizure</strong> – We recommend initiating antiseizure medication therapy in individuals who have had two or more unprovoked seizures (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). Such patients are at high risk for further unprovoked seizures. (See <a class="local">'Second unprovoked seizure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selection of antiseizure medication</strong> – The selection of antiseizure medication considers the type of epilepsy or epilepsy syndrome  (<a class="graphic graphic_table graphicRef78021" href="/z/d/graphic/78021.html" rel="external">table 3</a>) and potential side effects  (<a class="graphic graphic_table graphicRef59755" href="/z/d/graphic/59755.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef78896" href="/z/d/graphic/78896.html" rel="external">table 5</a>), as well as other prescribed medications and comorbidities. Patient age, patient sex, and cost and availability of medication may also be relevant factors. (See <a class="local">'Drug-related considerations'</a> above and <a class="local">'Seizure and epilepsy syndrome-related considerations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Consider drug interactions</strong> – In general, enzyme-inducing antiseizure medications (eg, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">oxcarbazepine</a>) are the most problematic for interactions with drugs such as <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, hormonal contraception, anti-cancer drugs, and anti-infective drugs. Specific interactions of antiseizure medications with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>. (See <a class="local">'Pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Impact of kidney and liver disease</strong> – Because antiseizure medications are either metabolized by the liver or excreted by the kidneys, renal and hepatic disease impacts on both the choice of antiseizure medication as well as the prescribing regimen. (See <a class="local">'Renal disease'</a> above and <a class="local">'Hepatic disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Teratogenic effects</strong> – Women of childbearing age should be counseled regarding possible teratogenic effects of antiseizure medications. <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">Folic acid</a> supplementation is recommended for all women of child-bearing potential. <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">Valproate</a> should be avoided and only prescribed if no other antiseizure medication is effective for that particular patient. (See <a class="local">'Women of childbearing age'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Consider comorbid psychiatric disorders</strong> – Patients with epilepsy have a higher-than-expected incidence of mood problems, anxiety, and depression. Antiseizure medications as a class have been associated with suicidality. Some antiseizure medications appear to have mood-stabilizing properties, while others may cause or exacerbate a depressed mood or provoke psychosis. Patients treated with antiseizure medications should be monitored for changes in mood and suicidality. (See <a class="local">'Psychiatric disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient education and follow-up</strong> – Successful treatment can be optimized by a systematic approach that includes patient education. The physician should emphasize the critical need to follow the prescribed drug regimen. Nonadherence to antiseizure medication treatment regimen is associated with increased risk of mortality, as well as hospitalization and injury. Regular outpatient follow-up appointments and the use of seizure calendars can help maximize the success of epilepsy treatment. (See <a class="local">'Initiation of antiseizure medication therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; 55:475.</a></li><li><a class="nounderline abstract_t">Nevalainen O, Ansakorpi H, Simola M, et al. Epilepsy-related clinical characteristics and mortality: a systematic review and meta-analysis. Neurology 2014; 83:1968.</a></li><li><a class="nounderline abstract_t">Krumholz A, Wiebe S, Gronseth GS, et al. Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2015; 84:1705.</a></li><li><a class="nounderline abstract_t">Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 2005; 365:2007.</a></li><li><a class="nounderline abstract_t">Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. First Seizure Trial Group (FIR.S.T. Group). Neurology 1993; 43:478.</a></li><li><a class="nounderline abstract_t">Kim LG, Johnson TL, Marson AG, et al. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol 2006; 5:317.</a></li><li><a class="nounderline abstract_t">Berg AT. Risk of recurrence after a first unprovoked seizure. Epilepsia 2008; 49 Suppl 1:13.</a></li><li><a class="nounderline abstract_t">Hauser WA, Rich SS, Lee JR, et al. Risk of recurrent seizures after two unprovoked seizures. N Engl J Med 1998; 338:429.</a></li><li><a class="nounderline abstract_t">Hauser WA, Rich SS, Annegers JF, Anderson VE. Seizure recurrence after a 1st unprovoked seizure: an extended follow-up. Neurology 1990; 40:1163.</a></li><li><a class="nounderline abstract_t">Musicco M, Beghi E, Solari A, Viani F. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. First Seizure Trial Group (FIRST Group). Neurology 1997; 49:991.</a></li><li><a class="nounderline abstract_t">Ramos Lizana J, Cassinello Garciá E, Carrasco Marina LL, et al. Seizure recurrence after a first unprovoked seizure in childhood: a prospective study. Epilepsia 2000; 41:1005.</a></li><li><a class="nounderline abstract_t">Vergara López S, Ramos-Jiménez C, Adrián de la Cruz Reyes L, et al. Epilepsy diagnosis based on one unprovoked seizure and ≥60% risk. A systematic review of the etiologies. Epilepsy Behav 2021; 125:108392.</a></li><li><a class="nounderline abstract_t">Kho LK, Lawn ND, Dunne JW, Linto J. First seizure presentation: do multiple seizures within 24 hours predict recurrence? Neurology 2006; 67:1047.</a></li><li><a class="nounderline abstract_t">Leone MA, Solari A, Beghi E, FIRST Group. Treatment of the first tonic-clonic seizure does not affect long-term remission of epilepsy. Neurology 2006; 67:2227.</a></li><li><a class="nounderline abstract_t">Das CP, Sawhney IM, Lal V, Prabhakar S. Risk of recurrence of seizures following single unprovoked idiopathic seizure. Neurol India 2000; 48:357.</a></li><li><a class="nounderline abstract_t">Chandra B. First seizure in adults: to treat or not to treat. Clin Neurol Neurosurg 1992; 94 Suppl:S61.</a></li><li><a class="nounderline abstract_t">Gilad R, Lampl Y, Gabbay U, et al. Early treatment of a single generalized tonic-clonic seizure to prevent recurrence. Arch Neurol 1996; 53:1149.</a></li><li><a class="nounderline abstract_t">Leone MA, Giussani G, Nolan SJ, et al. Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. Cochrane Database Syst Rev 2016; :CD007144.</a></li><li><a class="nounderline abstract_t">Leone MA, Vallalta R, Solari A, et al. Treatment of first tonic-clonic seizure does not affect mortality: long-term follow-up of a randomised clinical trial. J Neurol Neurosurg Psychiatry 2011; 82:924.</a></li><li><a class="nounderline abstract_t">Jacoby A, Gamble C, Doughty J, et al. Quality of life outcomes of immediate or delayed treatment of early epilepsy and single seizures. Neurology 2007; 68:1188.</a></li><li><a class="nounderline abstract_t">Hesdorffer DC, Benn EK, Cascino GD, Hauser WA. Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia 2009; 50:1102.</a></li><li><a class="nounderline abstract_t">Fields MC, Labovitz DL, French JA. Hospital-onset seizures: an inpatient study. JAMA Neurol 2013; 70:360.</a></li><li><a class="nounderline abstract_t">Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342:314.</a></li><li><a class="nounderline abstract_t">Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002; 58:S2.</a></li><li><a class="nounderline abstract_t">French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62:1252.</a></li><li><a class="nounderline abstract_t">Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013; 54:551.</a></li><li><a class="nounderline abstract_t">Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2018; 91:74.</a></li><li><a class="nounderline abstract_t">Nolan SJ, Marson AG, Weston J, Tudur Smith C. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev 2015; :CD001911.</a></li><li><a class="nounderline abstract_t">Nevitt SJ, Marson AG, Weston J, Tudur Smith C. Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev 2018; 8:CD001769.</a></li><li><a class="nounderline abstract_t">Chadwick DW, Anhut H, Greiner MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 1998; 51:1282.</a></li><li><a class="nounderline abstract_t">French J, Glue P, Friedman D, et al. Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes. Neurology 2016; 87:1242.</a></li><li><a class="nounderline abstract_t">Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999; 37:81.</a></li><li><a class="nounderline abstract_t">Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345:476.</a></li><li><a class="nounderline abstract_t">Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999; 40:601.</a></li><li><a class="nounderline abstract_t">Brodie MJ, Chadwick DW, Anhut H, et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002; 43:993.</a></li><li><a class="nounderline abstract_t">Kwan P, Brodie MJ, Kälviäinen R, et al. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol 2011; 10:881.</a></li><li><a class="nounderline abstract_t">Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107:165.</a></li><li><a class="nounderline abstract_t">Ramsay E, Faught E, Krumholz A, et al. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Epilepsia 2010; 51:1970.</a></li><li><a class="nounderline abstract_t">Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27:195.</a></li><li><a class="nounderline abstract_t">Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997; 27:205.</a></li><li><a class="nounderline abstract_t">Christe W, Krämer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26:451.</a></li><li><a class="nounderline abstract_t">Dam M, Ekberg R, Løyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3:70.</a></li><li><a class="nounderline abstract_t">Baulac M, Brodie MJ, Patten A, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 2012; 11:579.</a></li><li><a class="nounderline abstract_t">Baulac M, Patten A, Giorgi L. Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: results of a phase III, randomized, double-blind study. Epilepsia 2014; 55:1534.</a></li><li><a class="nounderline abstract_t">Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68:402.</a></li><li><a class="nounderline abstract_t">Trinka E, Marson AG, Van Paesschen W, et al. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry 2013; 84:1138.</a></li><li><a class="nounderline abstract_t">Brodie MJ, Wroe SJ, Dean AD, et al. Efficacy and Safety of Remacemide versus Carbamazepine in Newly Diagnosed Epilepsy: Comparison by Sequential Analysis. Epilepsy Behav 2002; 3:140.</a></li><li><a class="nounderline abstract_t">Baulac M, Rosenow F, Toledo M, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 2017; 16:43.</a></li><li><a class="nounderline abstract_t">Lattanzi S, Zaccara G, Giovannelli F, et al. Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis. Acta Neurol Scand 2019; 139:33.</a></li><li><a class="nounderline abstract_t">Perucca E, Brodie MJ, Kwan P, Tomson T. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol 2020; 19:544.</a></li><li><a class="nounderline abstract_t">Privitera MD. Evidence-based medicine and antiepileptic drugs. Epilepsia 1999; 40 Suppl 5:S47.</a></li><li><a class="nounderline abstract_t">Williamson PR, Marson AG, Tudur C, et al. Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials. J Eval Clin Pract 2000; 6:205.</a></li><li><a class="nounderline abstract_t">Gamble C, Williamson PR, Chadwick DW, Marson AG. A meta-analysis of individual patient responses to lamotrigine or carbamazepine monotherapy. Neurology 2006; 66:1310.</a></li><li><a class="nounderline abstract_t">Muller M, Marson AG, Williamson PR. Oxcarbazepine versus phenytoin monotherapy for epilepsy. Cochrane Database Syst Rev 2006; :CD003615.</a></li><li><a class="nounderline abstract_t">Tudur Smith C, Marson AG, Clough HE, Williamson PR. Carbamazepine versus phenytoin monotherapy for epilepsy. Cochrane Database Syst Rev 2002; :CD001911.</a></li><li><a class="nounderline abstract_t">Marson AG, Appleton R, Baker GA, et al. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technol Assess 2007; 11:iii.</a></li><li><a class="nounderline abstract_t">Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369:1000.</a></li><li><a class="nounderline abstract_t">Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369:1016.</a></li><li><a class="nounderline abstract_t">Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet 2021; 397:1363.</a></li><li><a class="nounderline abstract_t">Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet 2021; 397:1375.</a></li><li><a class="nounderline abstract_t">Chadwick D, Marson T. Choosing a first drug treatment for epilepsy after SANAD: randomized controlled trials, systematic reviews, guidelines and treating patients. Epilepsia 2007; 48:1259.</a></li><li><a class="nounderline abstract_t">Jacoby A, Sudell M, Tudur Smith C, et al. Quality-of-life outcomes of initiating treatment with standard and newer antiepileptic drugs in adults with new-onset epilepsy: findings from the SANAD trial. Epilepsia 2015; 56:460.</a></li><li><a class="nounderline abstract_t">French JA. First-choice drug for newly diagnosed epilepsy. Lancet 2007; 369:970.</a></li><li><a class="nounderline abstract_t">Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav 2005; 7 Suppl 1:S1.</a></li><li><a class="nounderline abstract_t">Shih JJ, Whitlock JB, Chimato N, et al. Epilepsy treatment in adults and adolescents: Expert opinion, 2016. Epilepsy Behav 2017; 69:186.</a></li><li><a class="nounderline abstract_t">Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007; 9:353.</a></li><li><a class="nounderline abstract_t">French JA, White HS, Klitgaard H, et al. Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia 2013; 54 Suppl 4:3.</a></li><li><a class="nounderline abstract_t">Gidal BE, Ferry J, Reyderman L, Piña-Garza JE. Use of extended-release and immediate-release anti-seizure medications with a long half-life to improve adherence in epilepsy: A guide for clinicians. Epilepsy Behav 2021; 120:107993.</a></li><li><a class="nounderline abstract_t">Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003; 2:473.</a></li><li><a class="nounderline abstract_t">Patsalos PN, Fröscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43:365.</a></li><li><a class="nounderline abstract_t">Johannessen SI, Landmark CJ. Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol 2010; 8:254.</a></li><li><a class="nounderline abstract_t">Gidal BE, French JA, Grossman P, Le Teuff G. Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology 2009; 72:419.</a></li><li><a class="nounderline abstract_t">Cazali N, Tran A, Treluyer JM, et al. Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol 2003; 56:526.</a></li><li><a class="nounderline abstract_t">Perucca P, Carter J, Vahle V, Gilliam FG. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology 2009; 72:1223.</a></li><li><a class="nounderline abstract_t">Hessen E, Lossius MI, Gjerstad L. Antiepileptic monotherapy significantly impairs normative scores on common tests of executive functions. Acta Neurol Scand 2009; 119:194.</a></li><li><a class="nounderline abstract_t">Motamedi G, Meador K. Epilepsy and cognition. Epilepsy Behav 2003; 4 Suppl 2:S25.</a></li><li><a class="nounderline abstract_t">Meador KJ. Cognitive and memory effects of the new antiepileptic drugs. Epilepsy Res 2006; 68:63.</a></li><li><a class="nounderline abstract_t">Koch MW, Polman SK. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev 2009; :CD006453.</a></li><li><a class="nounderline abstract_t">Yang CY, Dao RL, Lee TJ, et al. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology 2011; 77:2025.</a></li><li><a class="nounderline abstract_t">Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64:1134.</a></li><li class="breakAll">http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4344b1-01-FDA.pdf (Accessed on September 15, 2009).</li><li><a class="nounderline abstract_t">Kerr MP, Mensah S, Besag F, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia 2011; 52:2133.</a></li><li><a class="nounderline abstract_t">French JA, Wang S, Warnock B, Temkin N. Historical control monotherapy design in the treatment of epilepsy. Epilepsia 2010; 51:1936.</a></li><li><a class="nounderline abstract_t">French JA, Temkin NR, Shneker BF, et al. Lamotrigine XR conversion to monotherapy: first study using a historical control group. Neurotherapeutics 2012; 9:176.</a></li><li><a class="nounderline abstract_t">Chung S, Ceja H, Gawłowicz J, et al. Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study. Epilepsy Res 2012; 101:92.</a></li><li><a class="nounderline abstract_t">French J, Kwan P, Fakhoury T, et al. Pregabalin monotherapy in patients with partial-onset seizures: a historical-controlled trial. Neurology 2014; 82:590.</a></li><li><a class="nounderline abstract_t">Wechsler RT, Li G, French J, et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study. Epilepsia 2014; 55:1088.</a></li><li><a class="nounderline abstract_t">Sperling MR, French J, Jacobson MP, et al. Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies. Neurology 2016; 86:1095.</a></li><li><a class="nounderline abstract_t">Perucca E. Treatment of epilepsy in developing countries. BMJ 2007; 334:1175.</a></li><li><a class="nounderline abstract_t">Lüders HO, Turnbull J, Kaffashi F. Are the dichotomies generalized versus focal epilepsies and idiopathic versus symptomatic epilepsies still valid in modern epileptology? Epilepsia 2009; 50:1336.</a></li><li><a class="nounderline abstract_t">Bazil CW. Antiepileptic drugs in the 21st century. CNS Spectr 2001; 6:756.</a></li><li><a class="nounderline abstract_t">Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39:5.</a></li><li><a class="nounderline abstract_t">Gelisse P, Genton P, Kuate C, et al. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 2004; 45:1282.</a></li><li><a class="nounderline abstract_t">Doerrfuss JI, Kowski AB, Holtkamp M. Etiology-specific response to antiseizure medication in focal epilepsy. Epilepsia 2021; 62:2133.</a></li><li><a class="nounderline abstract_t">Ryvlin P, Montavont A, Nighoghossian N. Optimizing therapy of seizures in stroke patients. Neurology 2006; 67:S3.</a></li><li><a class="nounderline abstract_t">Vecht CJ, van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology 2006; 67:S10.</a></li><li><a class="nounderline abstract_t">Michelucci R. Optimizing therapy of seizures in neurosurgery. Neurology 2006; 67:S14.</a></li><li><a class="nounderline abstract_t">Lacerda G, Krummel T, Sabourdy C, et al. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006; 67:S28.</a></li><li><a class="nounderline abstract_t">Israni RK, Kasbekar N, Haynes K, Berns JS. Use of antiepileptic drugs in patients with kidney disease. Semin Dial 2006; 19:408.</a></li><li><a class="nounderline abstract_t">Sheth RD. Metabolic concerns associated with antiepileptic medications. Neurology 2004; 63:S24.</a></li><li><a class="nounderline abstract_t">Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure 2006; 15:156.</a></li><li><a class="nounderline abstract_t">Gabbs MG, Barry JJ. The link between mood disorders and epilepsy: why is it important to diagnose and treat? Adv Stud Med 2005; 5:S572.</a></li><li><a class="nounderline abstract_t">Ettinger AB, Reed ML, Goldberg JF, Hirschfeld RM. Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders. Neurology 2005; 65:535.</a></li><li><a class="nounderline abstract_t">Kanner AM. Depression in epilepsy: a neurobiologic perspective. Epilepsy Curr 2005; 5:21.</a></li><li><a class="nounderline abstract_t">Beyenburg S, Mitchell AJ, Schmidt D, et al. Anxiety in patients with epilepsy: systematic review and suggestions for clinical management. Epilepsy Behav 2005; 7:161.</a></li><li><a class="nounderline abstract_t">Karceski SC. Exploring the connection between mood disorders and epilepsy. Pract Neurol 2005; 4:24.</a></li><li><a class="nounderline abstract_t">Gilliam FG, Mendiratta A, Pack AM, Bazil CW. Epilepsy and common comorbidities: improving the outpatient epilepsy encounter. Epileptic Disord 2005; 7 Suppl 1:S27.</a></li><li><a class="nounderline abstract_t">Brodtkorb E, Mula M. Optimizing therapy of seizures in adult patients with psychiatric comorbidity. Neurology 2006; 67:S39.</a></li><li><a class="nounderline abstract_t">García-Morales I, de la Peña Mayor P, Kanner AM. Psychiatric comorbidities in epilepsy: identification and treatment. Neurologist 2008; 14:S15.</a></li><li><a class="nounderline abstract_t">Labiner DM, Ettinger AB, Fakhoury TA, et al. Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. Epilepsia 2009; 50:434.</a></li><li><a class="nounderline abstract_t">Mula M, Hesdorffer DC, Trimble M, Sander JW. The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia 2009; 50:1072.</a></li><li><a class="nounderline abstract_t">Chen B, Choi H, Hirsch LJ, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav 2017; 76:24.</a></li><li><a class="nounderline abstract_t">De Simone R, Ranieri A, Marano E, et al. Migraine and epilepsy: clinical and pathophysiological relations. Neurol Sci 2007; 28 Suppl 2:S150.</a></li><li><a class="nounderline abstract_t">Bigal ME, Lipton RB, Cohen J, Silberstein SD. Epilepsy and migraine. Epilepsy Behav 2003; 4 Suppl 2:S13.</a></li><li><a class="nounderline abstract_t">Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005; 57:252.</a></li><li><a class="nounderline abstract_t">Pack A. Effects of Treatment on Endocrine Function in Patients with Epilepsy. Curr Treat Options Neurol 2005; 7:273.</a></li><li><a class="nounderline abstract_t">Pack AM, Morrell MJ, Randall A, et al. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 2008; 70:1586.</a></li><li><a class="nounderline abstract_t">Mattson RH, Gidal BE. Fractures, epilepsy, and antiepileptic drugs. Epilepsy Behav 2004; 5 Suppl 2:S36.</a></li><li><a class="nounderline abstract_t">Tomson T, Beghi E, Sundqvist A, Johannessen SI. Medical risks in epilepsy: a review with focus on physical injuries, mortality, traffic accidents and their prevention. Epilepsy Res 2004; 60:1.</a></li><li><a class="nounderline abstract_t">Steinhoff BJ. Optimizing therapy of seizures in patients with endocrine disorders. Neurology 2006; 67:S23.</a></li><li><a class="nounderline abstract_t">Lossius MI, Taubøll E, Mowinckel P, Gjerstad L. Reversible effects of antiepileptic drugs on thyroid hormones in men and women with epilepsy: a prospective randomized double-blind withdrawal study. Epilepsy Behav 2009; 16:64.</a></li><li><a class="nounderline abstract_t">Bhigjee AI, Rosemberg S. Optimizing therapy of seizures in patients with HIV and cysticercosis. Neurology 2006; 67:S19.</a></li><li><a class="nounderline abstract_t">Birbeck GL, French JA, Perucca E, et al. Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. Epilepsia 2012; 53:207.</a></li><li><a class="nounderline abstract_t">Birbeck GL, French JA, Perucca E, et al. Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. Neurology 2012; 78:139.</a></li><li><a class="nounderline abstract_t">Yacoob Y, Bhigjee AI, Moodley P, Parboosing R. Sodium valproate and highly active antiretroviral therapy in HIV positive patients who develop new onset seizures. Seizure 2011; 20:80.</a></li><li><a class="nounderline abstract_t">Bullman J, Nicholls A, Van Landingham K, et al. Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. Epilepsia 2011; 52:1351.</a></li><li><a class="nounderline abstract_t">Kennebäck G, Bergfeldt L, Tomson T, et al. Carbamazepine induced bradycardia--a problem in general or only in susceptible patients? A 24-h long-term electrocardiogram study. Epilepsy Res 1992; 13:141.</a></li><li><a class="nounderline abstract_t">Saetre E, Abdelnoor M, Amlie JP, et al. Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine. Epilepsia 2009; 50:1841.</a></li><li><a class="nounderline abstract_t">Mintzer S, Skidmore CT, Abidin CJ, et al. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol 2009; 65:448.</a></li><li><a class="nounderline abstract_t">Erdemir A, Cullu N, Yiş U, et al. Evaluation of serum lipids and carotid artery intima media thickness in epileptic children treated with valproic acid. Brain Dev 2009; 31:713.</a></li><li><a class="nounderline abstract_t">Chuang YC, Chuang HY, Lin TK, et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia 2012; 53:120.</a></li><li><a class="nounderline abstract_t">Josephson CB, Wiebe S, Delgado-Garcia G, et al. Association of Enzyme-Inducing Antiseizure Drug Use With Long-term Cardiovascular Disease. JAMA Neurol 2021; 78:1367.</a></li><li><a class="nounderline abstract_t">Lee-Lane E, Torabi F, Lacey A, et al. Epilepsy, antiepileptic drugs, and the risk of major cardiovascular events. Epilepsia 2021; 62:1604.</a></li><li><a class="nounderline abstract_t">French JA, Pedley TA. Clinical practice. Initial management of epilepsy. N Engl J Med 2008; 359:166.</a></li><li><a class="nounderline abstract_t">Rahman A, Mican LM, Fischer C, Campbell AH. Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. Ann Pharmacother 2009; 43:822.</a></li><li><a class="nounderline abstract_t">Morrell MJ, Sarto GE, Shafer PO, et al. Health issues for women with epilepsy: a descriptive survey to assess knowledge and awareness among healthcare providers. J Womens Health Gend Based Med 2000; 9:959.</a></li><li><a class="nounderline abstract_t">Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology 1992; 42:149.</a></li><li><a class="nounderline abstract_t">Coulam CB, Annegers JF. Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 1979; 20:519.</a></li><li><a class="nounderline abstract_t">Zupanc ML. Antiepileptic drugs and hormonal contraceptives in adolescent women with epilepsy. Neurology 2006; 66:S37.</a></li><li><a class="nounderline abstract_t">ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.</a></li><li><a class="nounderline abstract_t">Herzog AG. Catamenial epilepsy: definition, prevalence pathophysiology and treatment. Seizure 2008; 17:151.</a></li><li><a class="nounderline abstract_t">Foldvary-Schaefer N, Falcone T. Catamenial epilepsy: pathophysiology, diagnosis, and management. Neurology 2003; 61:S2.</a></li><li><a class="nounderline abstract_t">Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia 1997; 38:1082.</a></li><li><a class="nounderline abstract_t">Reddy DS. The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy. Epilepsy Res 2009; 85:1.</a></li><li><a class="nounderline abstract_t">El-Khayat HA, Soliman NA, Tomoum HY, et al. Reproductive hormonal changes and catamenial pattern in adolescent females with epilepsy. Epilepsia 2008; 49:1619.</a></li><li><a class="nounderline abstract_t">Morrell MJ, Hamdy SF, Seale CG, Springer EA. Self-reported reproductive history in women with epilepsy: puberty onset and effects of menarche and menstrual cycle on seizures. Neurology 1998; 50:448.</a></li><li><a class="nounderline abstract_t">Marques-Assis L. [Influence of menstruation on epilepsy]. Arq Neuropsiquiatr 1981; 39:390.</a></li><li><a class="nounderline abstract_t">Herzog AG, Fowler KM, Sperling MR, et al. Variation of seizure frequency with ovulatory status of menstrual cycles. Epilepsia 2011; 52:1843.</a></li><li><a class="nounderline abstract_t">Kalinin VV, Zheleznova EV. Chronology and evolution of temporal lobe epilepsy and endocrine reproductive dysfunction in women: relationships to side of focus and catameniality. Epilepsy Behav 2007; 11:185.</a></li><li><a class="nounderline abstract_t">Quigg M, Smithson SD, Fowler KM, et al. Laterality and location influence catamenial seizure expression in women with partial epilepsy. Neurology 2009; 73:223.</a></li><li><a class="nounderline abstract_t">Herzog AG, Fowler KM, Sperling MR, et al. Distribution of seizures across the menstrual cycle in women with epilepsy. Epilepsia 2015; 56:e58.</a></li><li><a class="nounderline abstract_t">Feely M, Calvert R, Gibson J. Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants. Lancet 1982; 2:71.</a></li><li><a class="nounderline abstract_t">Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: tolerance avoided. J Neurol Neurosurg Psychiatry 1984; 47:1279.</a></li><li><a class="nounderline abstract_t">Lim LL, Foldvary N, Mascha E, Lee J. Acetazolamide in women with catamenial epilepsy. Epilepsia 2001; 42:746.</a></li><li><a class="nounderline abstract_t">Ansell B, Clarke E. Acetazolamide in Treatment of Epilepsy. Br Med J 1956; 1:650.</a></li><li><a class="nounderline abstract_t">Poser CH. Letter: Modification of therapy for exacerbation of seizures during menstruation. J Pediatr 1974; 84:779.</a></li><li><a class="nounderline abstract_t">Herzog AG, Fowler KM, Smithson SD, et al. Progesterone vs placebo therapy for women with epilepsy: A randomized clinical trial. Neurology 2012; 78:1959.</a></li><li><a class="nounderline abstract_t">Reddy DS, Rogawski MA. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics 2009; 6:392.</a></li><li><a class="nounderline abstract_t">Nohria V, Giller E. Ganaxolone. Neurotherapeutics 2007; 4:102.</a></li><li><a class="nounderline abstract_t">Haider Y, Barnett DB. Catamenial epilepsy and goserelin. Lancet 1991; 338:1530.</a></li><li><a class="nounderline abstract_t">Tomson T, Marson A, Boon P, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia 2015; 56:1006.</a></li><li><a class="nounderline abstract_t">Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47:1094.</a></li><li><a class="nounderline abstract_t">Perucca E. NICE guidance on newer drugs for epilepsy in adults. BMJ 2004; 328:1273.</a></li><li><a class="nounderline abstract_t">Faught E, Duh MS, Weiner JR, et al. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology 2008; 71:1572.</a></li><li><a class="nounderline abstract_t">Kaiboriboon K, Guevara M, Alldredge BK. Understanding herb and dietary supplement use in patients with epilepsy. Epilepsia 2009; 50:1927.</a></li><li><a class="nounderline abstract_t">Perucca P, Jacoby A, Marson AG, et al. Adverse antiepileptic drug effects in new-onset seizures: a case-control study. Neurology 2011; 76:273.</a></li><li><a class="nounderline abstract_t">Haut SR, Hall CB, Masur J, Lipton RB. Seizure occurrence: precipitants and prediction. Neurology 2007; 69:1905.</a></li><li><a class="nounderline abstract_t">Hoppe C, Poepel A, Elger CE. Epilepsy: accuracy of patient seizure counts. Arch Neurol 2007; 64:1595.</a></li><li><a class="nounderline abstract_t">Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49:1239.</a></li></ol></div><div id="topicVersionRevision">Topic 2212 Version 57.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24730690" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ILAE official report: a practical clinical definition of epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25339211" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Epilepsy-related clinical characteristics and mortality: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25901057" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15950714" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8450987" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. First Seizure Trial Group (FIR.S.T. Group)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16545748" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18184149" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk of recurrence after a first unprovoked seizure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9459646" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk of recurrent seizures after two unprovoked seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2381523" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Seizure recurrence after a 1st unprovoked seizure: an extended follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9339678" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. First Seizure Trial Group (FIRST Group).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10961628" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Seizure recurrence after a first unprovoked seizure in childhood: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34740089" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Epilepsy diagnosis based on one unprovoked seizure and≥60% risk. A systematic review of the etiologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17000974" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : First seizure presentation: do multiple seizures within 24 hours predict recurrence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17190950" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of the first tonic-clonic seizure does not affect long-term remission of epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11146601" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Risk of recurrence of seizures following single unprovoked idiopathic seizure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1320521" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : First seizure in adults: to treat or not to treat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8912488" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Early treatment of a single generalized tonic-clonic seizure to prevent recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27150433" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21531706" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment of first tonic-clonic seizure does not affect mortality: long-term follow-up of a randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17420402" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Quality of life outcomes of immediate or delayed treatment of early epilepsy and single seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19374657" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23319087" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hospital-onset seizures: an inpatient study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10660394" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Early identification of refractory epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11971127" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Staged approach to epilepsy management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15111659" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23350722" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29898971" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26275105" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30091458" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9818846" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27521437" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10515178" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7710545" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10386529" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12199724" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21889410" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12614309" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20633037" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9237054" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9237055" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9127726" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2645120" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22683226" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25109239" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: results of a phase III, randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17283312" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22933814" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12609415" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficacy and Safety of Remacemide versus Carbamazepine in Newly Diagnosed Epilepsy: Comparison by Sequential Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27889312" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30194755" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32109411" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : 30 years of second-generation antiseizure medications: impact and future perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10530694" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Evidence-based medicine and antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10970014" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16682660" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A meta-analysis of individual patient responses to lamotrigine or carbamazepine monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625587" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Oxcarbazepine versus phenytoin monotherapy for epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12076427" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Carbamazepine versus phenytoin monotherapy for epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17903391" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17382827" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17382828" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33838757" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33838758" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17442006" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Choosing a first drug treatment for epilepsy after SANAD: randomized controlled trials, systematic reviews, guidelines and treating patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25630353" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Quality-of-life outcomes of initiating treatment with standard and newer antiepileptic drugs in adults with new-onset epilepsy: findings from the SANAD trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17382806" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : First-choice drug for newly diagnosed epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16102515" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment of epilepsy in adults: expert opinion, 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28237319" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Epilepsy treatment in adults and adolescents: Expert opinion, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18077226" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Treatment of pediatric epilepsy: European expert opinion, 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23909849" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Development of new treatment approaches for epilepsy: unmet needs and opportunities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33971390" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Use of extended-release and immediate-release anti-seizure medications with a long half-life to improve adherence in epilepsy: A guide for clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12878435" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11952767" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The importance of drug interactions in epilepsy therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21358975" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Antiepileptic drug interactions - principles and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19188572" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Assessment of potential drug interactions in patients with epilepsy: impact of age and sex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14651727" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19349601" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18976320" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Antiepileptic monotherapy significantly impairs normative scores on common tests of executive functions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14527481" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Epilepsy and cognition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16377148" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Cognitive and memory effects of the new antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821367" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22116946" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Severe cutaneous adverse reactions to antiepileptic drugs in Asians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15824335" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15824335" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21955156" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20561024" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Historical control monotherapy design in the treatment of epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22139591" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Lamotrigine XR conversion to monotherapy: first study using a historical control group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22516508" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24415567" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pregabalin monotherapy in patients with partial-onset seizures: a historical-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24915838" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26911639" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17556434" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Treatment of epilepsy in developing countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19389146" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Are the dichotomies generalized versus focal epilepsies and idiopathic versus symptomatic epilepsies still valid in modern epileptology?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15492729" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Antiepileptic drugs in the 21st century.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9578007" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Antiepileptic drugs as a cause of worsening seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15461683" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34328218" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Etiology-specific response to antiseizure medication in focal epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17190919" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Optimizing therapy of seizures in stroke patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17190914" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Optimizing therapy of seizures in patients with brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17190915" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Optimizing therapy of seizures in neurosurgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17190918" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Optimizing therapy of seizures in patients with renal or hepatic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16970741" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Use of antiepileptic drugs in patients with kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15557547" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Metabolic concerns associated with antiepileptic medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16442314" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Antiepileptic drugs and liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The link between mood disorders and epilepsy: why is it important to diagnose and treat?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116112" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16059450" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Depression in epilepsy: a neurobiologic perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16054870" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Anxiety in patients with epilepsy: systematic review and suggestions for clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Exploring the connection between mood disorders and epilepsy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16120491" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Epilepsy and common comorbidities: improving the outpatient epilepsy encounter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17190921" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Optimizing therapy of seizures in adult patients with psychiatric comorbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19225366" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Psychiatric comorbidities in epilepsy: identification and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19016830" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19178563" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The role of titration schedule of topiramate for the development of depression in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28931473" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17508163" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Migraine and epilepsy: clinical and pathophysiological relations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14527480" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Epilepsy and migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668966" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15967090" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Effects of Treatment on Endocrine Function in Patients with Epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18443309" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15123010" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Fractures, epilepsy, and antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15279865" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Medical risks in epilepsy: a review with focus on physical injuries, mortality, traffic accidents and their prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17190917" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Optimizing therapy of seizures in patients with endocrine disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19646931" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Reversible effects of antiepileptic drugs on thyroid hormones in men and women with epilepsy: a prospective randomized double-blind withdrawal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17190916" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Optimizing therapy of seizures in patients with HIV and cysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22221159" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22218281" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20952215" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Sodium valproate and highly active antiretroviral therapy in HIV positive patients who develop new onset seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21635243" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1464298" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Carbamazepine induced bradycardia--a problem in general or only in susceptible patients? A 24-h long-term electrocardiogram study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19400874" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19296463" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064312" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Evaluation of serum lipids and carotid artery intima media thickness in epileptic children treated with valproic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22085257" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34605857" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Association of Enzyme-Inducing Antiseizure Drug Use With Long-term Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34046890" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Epilepsy, antiepileptic drugs, and the risk of major cardiovascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18614784" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Clinical practice. Initial management of epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19401471" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11103095" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Health issues for women with epilepsy: a descriptive survey to assess knowledge and awareness among healthcare providers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1574171" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/477641" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Do anticonvulsants reduce the efficacy of oral contraceptives?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567741" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Antiepileptic drugs and hormonal contraceptives in adolescent women with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16738183" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18164632" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Catamenial epilepsy: definition, prevalence pathophysiology and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504304" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Catamenial epilepsy: pathophysiology, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9579954" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Three patterns of catamenial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19406620" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18435756" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Reproductive hormonal changes and catamenial pattern in adolescent females with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Self-reported reproductive history in women with epilepsy: puberty onset and effects of menarche and menstrual cycle on seizures</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7340757" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : [Influence of menstruation on epilepsy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21756250" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Variation of seizure frequency with ovulatory status of menstrual cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17573242" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Chronology and evolution of temporal lobe epilepsy and endocrine reproductive dysfunction in women: relationships to side of focus and catameniality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19620611" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Laterality and location influence catamenial seizure expression in women with partial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25823700" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Distribution of seizures across the menstrual cycle in women with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6123810" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6392481" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Intermittent clobazam for catamenial epilepsy: tolerance avoided.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422329" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Acetazolamide in women with catamenial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20788515" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Acetazolamide in Treatment of Epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4856559" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Letter: Modification of therapy for exacerbation of seizures during menstruation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22649214" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Progesterone vs placebo therapy for women with epilepsy: A randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332335" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Neurosteroid replacement therapy for catamenial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17199022" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Ganaxolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1683955" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Catamenial epilepsy and goserelin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25851171" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Valproate in the treatment of epilepsy in girls and women of childbearing potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16886973" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15166043" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : NICE guidance on newer drugs for epilepsy in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18565827" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19486356" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Understanding herb and dietary supplement use in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21242496" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Adverse antiepileptic drug effects in new-onset seizures: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17998482" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Seizure occurrence: precipitants and prediction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17998441" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Epilepsy: accuracy of patient seizure counts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18397299" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
